Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
BGHL (GBP): NAV(s)

1h globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

0
BGHL (EUR): NAV(s)

1h globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

5
RIT Capital Partners Continues To Perform

13h seekingalpha
RIT Capital Partners once again beat the ACWI, returning 3.2% in the first half of the year compared to the index's 1.4%.
DBX GOOGL LNSTY RCP

0
AGM Statement

17h globenewswire
At an Annual General Meeting of Albion Enterprise VCT PLC, duly convened and held at the City of London Club, 19 Old Broad Street, London on 21 August 2018 the following resolutions were passed:
LNSTY AAEV

0
Estimated Net Asset Value as at 31 July 2018

2018-08-21 globenewswire
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
VTA LNSTY VTA

0
Shire plc: Rule 2.9 Announcement

2018-08-21 globenewswire
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
LNSTY

0
BGHL (GBP): NAV(s)

2018-08-21 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

0
BGHL (EUR): NAV(s)

2018-08-21 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

0
BGHL (EUR): NAV(s)

2018-08-20 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

0
BGHL (GBP): NAV(s)

2018-08-20 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

0
Sophos Sweeps Network and Endpoint Security Categories in CRN’s 2018 Annual Report Card – Again!

2018-08-19 globenewswire
BURLINGTON, Mass., Aug. 19, 2018 (GLOBE NEWSWIRE) -- Sophos (LSE: SOPH), a global leader in network and endpoint security, today announced that it has once again swept the Network and Endpoint Security categories of CRN’s 2018 Annual Report Card (ARC) awards. Sophos has been named “Overall Winner” in Network Security for the third year in a row, as well as “Overall Winner” in Endpoint Security. In both categories, Sophos ranked highest in all sub-categories based on solution provider satisfaction across product innovation, support, partnership, and the new sub-category, managed and cloud services.
SOPH LNSTY

0
Spending 55% Of The Net Rental Income On Interest Creates A Serious Problem: Intu Properties

2018-08-18 seekingalpha
Its cost of debt is more than twice as high as its competitors on the European Continent.
HMSNF INTU LNSTY CCRGF

1
Royal Dutch Shell: A Look At The Second-Quarter Earnings Results

2018-08-17 seekingalpha
Oil giant Royal Dutch Shell has reported revenues for the second-quarter 2018 of $96.77 billion, up 27.6% year over year and up 8.4% sequentially establishing a new revenue record.
RDS.B RDS.A SHLX RYDBF LNSTY RDSB RDSA RYDAF

0
Shire plc: Rule 2.9 Announcement

2018-08-17 globenewswire
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
LNSTY

0
BGHL (GBP): NAV(s)

2018-08-17 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
LNSTY

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 54211N101